Crystal Pharmatech returned to the American Association of Pharmaceutical Scientists (AAPS) 2022 PharmSci 360 conference alongside pharmaceutical industry players, buyers, and suppliers.
In the 3 years since this influential conference was last in-person, Crystal Pharmatech has transformed its capabilities and had the opportunity to put them on display at the Boston Convention and Exhibition Center in Boston, MA from October 17-19th.
Crystal Formulation Services (CFS) was featured in the Crystal Pharmatech booth at the conference and was represented by Xiaoxia (Jessica) Chen, Ph.D., CTO of Crystal Formulation Services.
CFS is a novel, small molecule and formulation CDMO located in Suzhou, China. CFS compliments the North American formulation development partnership with Candoo Pharmatech Company Inc.. With the recent expansion, Crystal Pharmatech now utilizes 120,000 sq.ft. of R&D and GMP facility space across New Jersey, USA; Ontario, Canada; and Suzhou, China.
Crystal Pharmatech’s Co-Founder and Vice President of Business Development, Robert Wenslow, Ph.D., provided special consultations at the conference. Wenslow was joined by a range of collaborative partners and key representatives, including Senior Scientist Mitulkumar (Mitul) Patel, Ph.D. and Head of Marketing Mailisi Heshuote, M.S..
Dr. Patel was featured at Simulation Plus’ forum discussion where he gave a presentation on the synergistic interplay between experimental and in silico work for drug development. The topic is representative of Crystal Pharmatech’s emphasis on using the most innovative and powerful technologies available to accelerate molecules to medicine.
Pharmaceutical conferences like the AAPS PharmSci 360 are vital for advancing the discovery of new medications and scientific research and crystallization process development. Dozens of biotechs learned about the new capabilities of Crystal Pharmatech and Crystal Formulation Services at Booth 320 as they networked with their future research and development solutions partner.
